Pharmacometabolomics in Drug Discovery and Development

Marques, Cátia; Marques, M. Matilde

doi:10.1016/b978-0-12-801238-3.11665-4

Cited by 2 publications

(1 citation statement)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolomics comprises pharmacometabolomics, an emerging branch that evaluates samples after exposure to a drug or another xenobiotic in order to establish possible models of treatment outcomes (e.g., efficacy or toxicity) and understand mechanisms of action. Pharmacometabolomics is a promising tool for personalized medicine, biomarker discovery, toxicology, and drug development, since it allows the elucidation of exposure-related alterations in biological pathways and their implications in downstream physiological and pathological conditions [2][3][4]. Metabolomics studies can also be employed to understand the pathophysiological alterations that occur in biological systems.…”

Section: Introductionmentioning

confidence: 99%

An Optimised MS-Based Versatile Untargeted Metabolomics Protocol

Marques

Justino

2023

Separations

View full text Add to dashboard Cite

Untargeted metabolomics approaches require complex samples containing the endogenous metabolites of a biological system. Here, we describe a set of protocols that can be applied to various types of samples, including prokaryotic and eukaryotic cells, as well as animal and human samples. Following a single extraction step, samples are analysed using different chromatographic conditions coupled to high-resolution mass spectrometry. Quantification of metabolite changes between samples is performed without internal standards, using peak areas from extracted ion chromatograms for statistical analysis. Bioinformatics annotation of the results allows a pathway- and process-oriented analysis across biological sample conditions, allowing a complete pathway interrogation.

show abstract

Section: Introductionmentioning

confidence: 99%